Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
MWN-AI** Summary
Insulet Corporation (NASDAQ: PODD) has officially announced the compatibility of its Omnipod® 5 App with the Dexcom G7 Continuous Glucose Monitoring (CGM) System, now available to all U.S. users. This integration marks a significant advancement in diabetes management, allowing patients to manage their insulin delivery seamlessly from their iPhones, enhancing convenience and user experience.
The Omnipod 5 Automated Insulin Delivery (AID) System, known for its tubeless design, actively adjusts insulin delivery every five minutes and provides autocorrection for high glucose levels, ensuring safety day and night. The app allows users to easily bolus, change Pods, and access valuable insights, all from their smartphones, reducing the need for additional devices.
Eric Benjamin, Insulet's Chief Product and Customer Experience Officer, emphasized that this development supports their mission to offer innovative solutions for diabetes management. The integration of the Dexcom G7 sensor simplifies the diabetes care routine for users, letting them manage blood glucose levels with fewer devices—a significant benefit for those balancing multiple aspects of diabetes management.
Garrett Vogel, a long-time Omnipod user, shared his positive experience with the app, highlighting its convenience over the previous Controller. He expressed that the app not only reduces stress but also has made his diabetes management more efficient.
The Omnipod 5 App, compatible with both Dexcom G7 and G6, can now be downloaded from the Apple App Store, providing users with a powerful tool for diabetes management. Insulet remains committed to advancing diabetes technology to enhance the quality of life for individuals living with diabetes. For more information, visit omnipod.com or insulet.com.
MWN-AI** Analysis
The recent announcement from Insulet Corporation regarding the compatibility of the Omnipod® 5 App with the Dexcom G7 CGM system presents a significant opportunity for investors to assess the potential growth of Insulet's market share in diabetes management technology. As a leader in tubeless insulin pump technology, Insulet's strategic move to integrate the Dexcom G7 sensor positions them advantageously within a rapidly evolving healthcare landscape focused on convenience and user engagement.
This integration simplifies the diabetes management process by enabling patients to control their insulin delivery directly from their iPhones, thereby eliminating the need for cumbersome devices. With features that allow for proactive insulin adjustments every five minutes and autocorrections for high glucose levels, the Omnipod 5 App offers enhanced user experience and better blood glucose control, which can boost customer satisfaction and retention.
Moreover, the introduction of user testimonials, such as that of Garrett Vogel, highlights the app's positive impact on users' daily lives. This direct line to the consumer experience can foster brand loyalty and potentially lead to an expanding user base as word-of-mouth and social proof play critical roles in healthcare decisions.
Financially, investors should keep in mind that the diabetes management market continues to grow, as an increasing number of people are diagnosed with diabetes, particularly type 1 diabetes. The competitive advantage gained through this integration could bolster Insulet's revenue streams substantially in the coming quarters. The ease of usage provided by mobile integration can also open doors for partnerships with other healthcare technology firms.
In conclusion, as Insulet’s Omnipod 5 continues to demonstrate improved patient outcomes, shareholders can be optimistic about potential stock value increase, especially if Insulet capitalizes on this innovative integration and further enhances its product offerings.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Dexcom G7 sensor integration offers more customers the ability to manage diabetes from their iPhone, for additional convenience
Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, is excited to announce that the Omnipod ® 5 App for iPhone is now compatible with the Dexcom G7 Continuous Glucose Monitoring (CGM) System.
With this latest integration, the Omnipod 5 Automated Insulin Delivery (AID) System combines the benefits of tubeless AID and Dexcom’s latest diabetes management technology, all conveniently controlled from an iPhone.
"This integration represents a major milestone in our commitment to providing innovative solutions for diabetes management,” said Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.”
Omnipod 5 proactively adjusts insulin delivery every five minutes, autocorrects for high glucose, and helps protect against lows*, day and night—even while you sleep. The Omnipod 5 App for iPhone, available in the U.S., offers full control of Omnipod 5 including the ability to bolus, change a Pod, adjust settings, access valuable insights, and more.
“The Omnipod 5 App for iPhone means less stress with better control! Plus, I feel like I lost a few pounds, since I don't have to carry around a Controller anymore,” joked Garrett Vogel, a nationally syndicated radio personality who has lived with type 1 diabetes for 30 years and has been using Omnipod 5 since 2023. Garrett was previously using Omnipod 5 with Dexcom G7 and the Controller. “I thought bolusing with the Controller was easy, but the Omnipod 5 App on my iPhone makes it even easier. I love it.”
The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store.
Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit https://www.omnipod.com/innovation .
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com .
*Brown S. et al. Diabetes Care. 2021;44:1630-1640. Sherr JL, et al. Diabetes Care. 2022. 45(8):1907–1910. Pasquel FJ et al. JAMA Network Open. 2024;8(2): e2459348. Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people with type 2 diabetes aged 18-75 years. Time above range and below range results measured by CGM.
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610766006/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7717
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
FAQ**
How does the integration of the Dexcom G7 sensor with the Omnipod 5 App represent a strategic advancement for Insulet Corporation (PODD) in the competitive diabetes management market?
What feedback have early users provided regarding the compatibility of the Dexcom G7 sensor with the Omnipod 5 App from Insulet Corporation (PODD)?
What impact do you anticipate the Dexcom G7 and Omnipod 5 integration will have on Insulet Corporation (PODD)'s market share and customer acquisition in the diabetes management sector?
How is Insulet Corporation (PODD) planning to leverage the new features of the Omnipod 5 App to enhance customer experience and retention in a rapidly evolving diabetes technology landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Insulet Corporation (NASDAQ: PODD).
NASDAQ: PODD
PODD Trading
1.37% G/L:
$236.685 Last:
291,064 Volume:
$234.77 Open:
